

## Tables

**Table 1 – Baseline characteristics**

	<i>Face-forward positioning (n=...)</i>	<i>Face-down positioning (n=...)</i>
<i>Age (years) – median (IQR)</i>		
<i>Male – no. (%)</i>		
<i>Ethnicity – no. (%)</i>		
<i>White</i>		
<i>Black</i>		
<i>Asian</i>		
<i>Mixed</i>		
<i>Other</i>		
<i>Laterality – Left Side – no. (%)</i>		
<i>Duration of symptoms (months) – median (IQR)</i>		
<i>BCVA (Best-Corrected Visual Acuity) – median (IQR)</i>		
<i>Lens Status – Phakic – no (%)</i>		
<i>Macular hole diameter on OCT – median (IQR)</i>		
<i>Quality of life VFQ-25 – median (IQR)</i>		

**Table 2 – Main results for primary outcomes**

	<b>Face-forward positioning (n=...)</b>	<b>Face-down positioning (n=...)</b>	<b>Odds Ratio (95% CI)</b>	<b>P-value</b>
<i>Successful closure of macular hole - n (%)</i>				

**Table 3 – Main results for dichotomous secondary outcomes**

	<b>Face-forward positioning (n=...)</b>	<b>Face-down positioning (n=...)</b>	<b>Odds Ratio (95% CI)</b>	<b>P-value</b>
<i>Further surgery for macular holes, performed or planned, of those with unsuccessful closure of macular hole –n(%)</i>				
<i>Dichotomised Patient- reported experience of positioning at 3 months- n(%)</i>				
<i>Patient reported outcome, if they would still have elected to have the operation</i>				
<i>Yes – n(%)</i>				
<i>Yes/Don't know (sensitivity analysis) – n(%)</i>				

**Table 4 – Main results for transformed continuous secondary outcomes**

	<b>Face-forward positioning (n=...)</b>	<b>Face-down positioning (n=...)</b>	<b>Regression coefficient (95% CI)</b>	<b>P-value</b>
<i>LogMAR conversion of Best corrected visual acuity (BCVA) using standard Snellen chart at 6m at 3 months - mean (sd)</i>				
<i>Logistic transformation of Patient-reported health and quality of life as assessed at 3 months using National Eye Institute Visual Function Questionnaire (VFQ-25) – mean (sd)</i>				

**Table 5- Main results for untransformed secondary outcomes**

	<b>Face-forward positioning (n=...)</b>	<b>Face-down positioning (n=...)</b>
<i>Best-corrected Visual Acuity (BCVA) using standard Snellen chart at 6m at 3 months - median (IQR)</i>		
<i>Patient-reported health and quality of life as assessed at 3 months using National Eye Institute Visual Function Questionnaire (VFQ-25) – median (IQR)</i>		
<i>Patient-reported experience of positioning at 3 months- median (IQR)</i>		

**Table 6 – Patient reported outcome, if they would still have elected to have the operation**

	<b>Face-forward positioning (n=...)</b>	<b>Face-down positioning (n=...)</b>
<i>Yes – n(%)</i>		
<i>No - n(%)</i>		
<i>Don't know - n(%)</i>		
<i>Missing - n(%)</i>		

**Table 7 – Combined surgery (removal of patient’s lens as a prophylactic procedure) by site.**

<b>Site</b>	<b>Combined surgery (n%) in total)</b>
Site A – n(%)	
Site B – n(%)	
Site C – n(%)	
Site D – n(%)	
Site E –n(%)	
Site F –n(%)	
Site G –n(%)	
Site H –n(%)	
Site I –n(%)	

**Table 8 – Number of participants with non-missing data**

<b>Outcome</b>	<b>Face-forward positioning (n=.)</b>	<b>Face-down positioning (n=.)</b>
<i>Further surgery for macular holes, performed or planned, of those with unsuccessful closure of macular hole –n(%)</i>		
<i>Best-corrected visual acuity (BCVA) measured using Snellen charts at a standard distance of 6 metres– n(%)</i>		
<i>Patient-reported experience of positioning at 3 months – n(%)</i>		
<i>Patient-reported health and quality of life as assessed at baseline and at 3 months using National Eye Institute Visual Function Questionnaire (VFQ-25) – n(%)</i>		
<i>Patient reported outcome, if they would still have elected to have the operation – n(%)</i>		

**Table 9 – Number of patients who experience complications in surgery and number of patients who with complications who withdrew from the trial, by treatment arm.**

	<i>Face-forward positioning (n=.)</i>	<i>Face-down positioning (n=.)</i>
Number of patients with complications during surgery		
Number of patient with complications during surgery who then withdrew from the trial		

**Table 10 – Number of Patients who experienced a Serious Adverse Event, by treatment arm and if this event was expected or unexpected.**

	<i>Face-forward positioning (n=.)</i>	<i>Face-down positioning (n=.)</i>
Number of patients who experienced a Serious Adverse Event which was expected		
Number of patients who experienced a Serious Adverse Event which was not expected		



**Table 11 – The number of patients for each BCVA category, and the corresponding conversion, by treatment arm.**

	<i>Face-forward positioning (n=.)</i>	<i>Face-down positioning (n=.)</i>
Counting fingers (CF) substituted for 2.10		
Hand movement (HM) substituted for 2.40		
Perception of light (PL) substituted for 2.70		
No perception of light (NPL) substituted for 3.00		